← Leaderboards
Samuel G Katz
Brigham And Women'S Hospital
$6,636,148
Attributed
$7,118,432
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2010–24$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,118,432 · 8
By mechanism
R01$2,317,426 · 1
RF1$1,969,620 · 1
R21$1,823,545 · 4
K08$672,841 · 1
R03$335,000 · 1
Top collaborators
- Michael E Hurwitz4 shared
- Elias Lolis2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Rachael Ann Clark$20,922,246
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsApoptoticCellsMediatingPathway InteractionsResponseSignal TransductionApoptosisCell SurvivalIn VitroCell DeathPlayCessation Of LifeStimulusIn VivoRegulationHomeostasisGenesPhenotypeExhibitsOuter Mitochondrial MembraneMitochondriaFamily MemberLigands
Grant awards (22)
Cell Death Regulation by Pro-Apoptotic BOK in Tauopathies$1,969,620
RF1 · FY2024 · NS · contact PI
Contribution of Mitochondrial Associated Membrane (MAM) Signaling to Neurodegeneration$335,000
R03 · FY2024 · AG · contact PI
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$185,977
R21 · FY2024 · CA · contact PI
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$84,638
R21 · FY2024 · CA · contact PI
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$33,048
R21 · FY2024 · CA · contact PI
Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming$234,919
R21 · FY2023 · CA · contact PI
Adoptive Cellular Therapy of T Cell Lymphoma$230,220
R21 · FY2022 · CA · contact PI
Adoptive Cellular Therapy of T Cell Lymphoma$195,766
R21 · FY2021 · CA · contact PI
Cell Death Regulation by Pro-Apoptotic BOK in Cardiomyocytes$496,239
R01 · FY2020 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK in Cardiomyocytes$513,114
R01 · FY2019 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK in Cardiomyocytes$436,242
R01 · FY2018 · HL · contact PI
Multifactor mRNA Mediated T Cell Reprogramming for Systemic Lupus Erythematosus$167,500
R21 · FY2018 · AI · contact PI
Cell Death Regulation by Pro-Apoptotic BOK in Cardiomyocytes$436,242
R01 · FY2017 · HL · contact PI
Multifactor mRNA Mediated T Cell Reprogramming for Systemic Lupus Erythematosus$293,125
R21 · FY2017 · AI · contact PI
Cell Death Regulation by Pro-Apoptotic BOK in Cardiomyocytes$435,589
R01 · FY2016 · HL · contact PI
SYNERGIZING PRO-APOPTOTIC AND CAR-T CELL IMMUNOTHERAPY FOR MANTLE CELL LYMPHOMA$181,069
R21 · FY2016 · CA · contact PI
SYNERGIZING PRO-APOPTOTIC AND CAR-T CELL IMMUNOTHERAPY FOR MANTLE CELL LYMPHOMA$217,283
R21 · FY2015 · CA · contact PI
Cell Death Regulation by Pro-Apoptotic BOK During Hematopoiesis$133,272
K08 · FY2014 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK During Hematopoiesis$133,272
K08 · FY2013 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK During Hematopoiesis$132,381
K08 · FY2012 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK During Hematopoiesis$136,958
K08 · FY2011 · HL · contact PI
Cell Death Regulation by Pro-Apoptotic BOK During Hematopoiesis$136,958
K08 · FY2010 · HL · contact PI